NSG BioLabs, Singapore’s premier provider of biotech laboratory and office space, has teamed up with Enterprise Singapore and Merck to propel the biotech sector.
Additionally, NSG BioLabs has secured a US$14.5m financing round, led by Celadon Partners and ClayvstBio. “NSG BioLabs is committed to supporting innovators and proud to have helped in Singapore's growing biotech ecosystem,” said Daphne Teo, CEO and Founder of NSG BioLabs. “Our partnerships with EnterpriseSG and Merck signify the importance of a collaborative spirit, and we hope to spur greater collaboration among other stakeholders to benefit the biotech industry in Singapore and the Asia Pacific region.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: